Mitotane,an orphan drug with narrow therapeutic window and significant interindividual variability for treating adrenocortical carcinoma,requires therapeutic drug monitoring[1].Current detection methods fail to accura...Mitotane,an orphan drug with narrow therapeutic window and significant interindividual variability for treating adrenocortical carcinoma,requires therapeutic drug monitoring[1].Current detection methods fail to accurately measure plasma drug concentrations after a high-fat meal,and the reasons behind the significant pharmacokinetic variability among individuals remain unclear,complicating individualized treatment[2,3].During our therapeutic drug monitoring process,we found that hyperlipidemic patients are more likely to reach the target drug concentration and experience concurrent neurotoxicity.展开更多
基金supported by 1·3·5 Project for Disciplines of ExcellenceeClinical Research Fund,West China Hospital,Sichuan University,China(Grant No.:23HXFH027)Foundation of Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province,China(Grant No.:FYYFEJB2024002)The Key Research and Development Program of Sichuan Province,China(Grant No.:2024YFFK0334).
文摘Mitotane,an orphan drug with narrow therapeutic window and significant interindividual variability for treating adrenocortical carcinoma,requires therapeutic drug monitoring[1].Current detection methods fail to accurately measure plasma drug concentrations after a high-fat meal,and the reasons behind the significant pharmacokinetic variability among individuals remain unclear,complicating individualized treatment[2,3].During our therapeutic drug monitoring process,we found that hyperlipidemic patients are more likely to reach the target drug concentration and experience concurrent neurotoxicity.
